⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31522061 | 1.00 | — | — | |
| SCHEMBL1559927 | 1.00 | — | — | |
| SCHEMBL17550009 | 0.91 | TSHR (0.53) | — | |
| SCHEMBL4636343 | 0.89 | TSHR (0.53) | — | |
| SCHEMBL7062564 | 0.88 | ALDH1A1 (0.47) | — | |
| SCHEMBL40046 | 0.87 | — | — | |
| SCHEMBL8192368 | 0.87 | — | — | |
| Cyclopentanol SCHEMBL971085 | 0.85 | TSHR (0.62) | — | |
| Hydrochloric Acid SCHEMBL3673085 | 0.84 | — | — | |
| Cyclohexanol SCHEMBL973289 | 0.82 | TSHR (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3394068-B1 | TDO2 INHIBITORS | GENENTECH INC (US) | 2024-09-11 | — | — | EP | claimed |
| WO-2024114814-A1 | JAK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | ONQUALITY PHARMACEUTICALS CHINA LTD (CN) | 2024-06-06 | — | — | WO | claimed |
| EP-3764821-B1 | FOAM CONTROL | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-08-31 | — | — | EP | claimed |
| CN-110072864-A | TDO2 INHIBITORS | 基因泰克公司 | 2019-07-30 | — | — | CN | claimed |
| US-8883776-B2 | Cycloalkyloxy- and heterocycloalkyloxypyridine compounds as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | claimed |
| EP-2222664-B1 | CYCLOALKYLOXY- AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-29 | — | — | EP | claimed |
| EP-2222664-A1 | CYCLOALKYLOXY-AND HET ROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2010-09-01 | — | — | EP | claimed |
| WO-2009067401-A1 | CYCLOALKYLOXY-AND HETΞROCYCLOALKY- LOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-28 | — | — | WO | claimed |
| US-20090131415-A1 | CYCLOALKYLOXY-AND HETEROCYCLOALKYLOXYPYRIDINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-21 | — | — | US | claimed |
| US-12390437-B2 | Itaconic acid derivatives and uses thereof intreating an inflammatory disease or a disease associated with an undesirable immune response | SITRYX THERAPEUTICS LIMITED (GB) | 2025-08-19 | — | — | US | disclosed |
| EP-4532473-A1 | AMINOHETEROARYL KINASE INHIBITORS | Allorion Therapeutics Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-119775531-A | Synthesis method and application of intrinsic conductive epoxy resin | 上海信斯帝克新材料有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119343333-A | Amino heteroaryl kinase inhibitors | 安锐生物医药公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024218296-A1 | COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-24 | — | — | WO | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1757599-A1 | INDOLE DERIVATIVES HAVING PIPERIDINE RINGS | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20050256103-A1 | Indole derivative having piperidine ring | EISAI CO., LTD. | 2005-11-17 | — | — | US | disclosed |
| WO-2004108668-A2 | ALPHA-7 NEURONAL NICOTINIC RECEPTOR LIGANDS: COMPOSITIONS AND METHODS OF USE | TARGACEPT, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | disclosed |